|
June 9, 2016
|
Highlights from ASCO |
|
Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development. Read more. |
|
Expanded access programs allow patients to use investigational treatments, medical devices, or tests, before they receive FDA approval. Read more. |
|
Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients' lives. But treatment outcomes in clinical trial settings don't always translate into comparable real-world clinical value. Read more. |
Top oncology content |
|
|
|
|
We welcome your feedback!
Please send your comments to:
Aubrey Westgate
Executive Editor
Managed Healthcare Executive
[email protected] |
DISCLAIMER:
This information has been independently developed and provided by the editors of Managed Healthcare Executive. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
